New York, NY -- (SBWire) -- 03/06/2020 --Shingles may be a Vaccines are biological products which are wont to prevent the occurrence of an outsized number of diseases. Vaccines protect against quite 25 debilitating or life-threatening diseases, including measles, polio, tetanus, diphtheria, meningitis, influenza, tetanus, typhoid and cervical cancer. Vaccines constitutes of a strain of disease-causing microorganism which is present within the sort of killed or weakened state. Vaccines are often classified on the idea of strain or serotype i.e. monovalent vaccines and multivalent vaccines. Vaccines could also be monovalent or multivalent. A monovalent vaccine contains one strain of one antigen (e.g. Measles vaccine), whereas a multivalent vaccine contains two or more strains/serotypes of an equivalent antigen (e.g. OPV).
Get Access To Free Sample Pages:https://www.marketindustryreports.com/pdf/125
Major key Players:
GlaxoSmithKline plc. And Merck & Co., Inc.and Others.
Shingles Vaccine Market Segmentation:
By Product:
-Shingrix
-Zostavax
By Patient Type:
-Pediatric Patients
-Adult Patients
Get Reasonable discount:https://www.marketindustryreports.com/discount/125
End User:
-Dermatology Centers
-Aesthetic Clinics
-Hospitals
Highlights by Global Shingles Vaccine Market Report:
-Intact analysis of major driving factors and ongoing trends based on each Shingles Vaccine market segment and sub-segment.
-Deep evaluation of emerging technological advancements in the global Shingles Vaccine market.
-Extensive estimation of the key manufacturers in the Shingles Vaccine market with assessment of market size, share, growth rate, and revenue.
-Detailed study of historical market scenario of the Shingles Vaccine market including forecast estimations up to 2030.
North America is estimated to account for the largest market share in the global shingles vaccine market. The large share of this region can be attributed to several factors such as availability of advanced healthcare facilities, presence of major players in this region, supportive government regulations, and convenience of systematic & favorable health insurance, among others.
Rising prevalence & incidences of shingles is anticipated to ensure a strong demand for shingles vaccination products worldwide. For instance, incidences of shingles have significantly risen in the US, with incidence rate among individuals belonging to the age group of 50-59 years, climbing from ~4.1 in 1998 to approximately 7.9 per 1000 people in 2016. Moreover, rising geriatric population has been one of the pivotal factors in contributing to the growth of the global shingles market. However, high costs associated with development & storage of vaccines, are likely to restrain the market to a certain extent.
Table of Content
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.5 Market by Application
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Shingles Vaccine Market Size
2.2 Shingles Vaccine Growth Trends by Regions
2.3 Industry Trends
3 Market Share by Key Players
3.1 Shingles Vaccine Market Size by Manufacturers
3.2 Shingles Vaccine Key Players Head office and Area Served
3.3 Key Players Shingles Vaccine Product/Solution/Service
3.4 Date of Enter into Shingles Vaccine Market
3.5 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
4.1 Global Shingles Vaccine Sales by Product
4.2 Global Shingles Vaccine Revenue by Product
4.3 Shingles Vaccine Price by Product
5 Breakdown Data by End User
5.1 Overview
5.2 Global Shingles Vaccine Breakdown Data by End User
Contact Us-
Email: sales@marketindustryreports.com
Phone: + 91 8956767535
Website: https://www.marketindustryreports.com
Shingles Vaccine Market - Growth, Trends, and Forecast (2019 - 2030): GlaxoSmithKline plc.and Merck & Co.Inc.:Cagr 7.4%
Shingles is an infectious disease which is caused by the reactivation of the chickenpox virus or herpes zoster. The common symptoms associated with this infection are development of rashes, ulcers blister and redness on the skin; exhaustion, and itching among others. Vaccines available for the treatment of shingles are Zostavax and Shingrix, which are manufactured by Merck & Co., Inc., & GlaxoSmithKline plc respectively.